Recent outbreaks, like the deadly Bundibugyo ebolavirus, are a reminder of how quickly dangerous pathogens can emerge and spread, but they also hint at what is possible when the right capabilities, pa...

CEPI is investing US$3.9 million in three research projects that will turn real-time outbreak data into actionable insights to guide the Bundibugyo ebolavirus response in the DRC and support vaccine t...

The funding will advance clinical testing of Immunoscript's thermostable next-generation RNA vaccine platform.

Over 120 experts working across the vaccine and epidemic preparedness research ecosystem in Indonesia and the region are taking part in the table-top event in Jakarta.

A new outbreak of mpox in Guinea-Bissau, the first recorded in the country, is a stark reminder that the virus remains a global threat. Mpox is not a new disease, but since the virus began spreading m...

The first 100 days of the Bundibugyo outbreak show how far epidemic response has advanced and how far it still has to go. It's painful proof that in a deadly epidemic, even faster than ever is often n...

CEPI-backed studies will analyse blood samples from thousands of people who have already been vaccinated against Zaire ebolavirus, with first results expected within months.

A tragic milestone was reached this month as the Bundibugyo ebolavirus outbreak – the fastest-growing Ebola outbreak on record - continues to escalate, with more than 1,400 deaths now recorded. As the...

No vaccine is currently approved against the virus. The rVSV vaccine candidate could become an important tool for Bundibugyo outbreak control and response.

The jab could be ready to send to the Democratic Republic of Congo within weeks

Aurélia Nguyen, CEPI’s Deputy CEO, explains how CEPI is supporting the global response to the Bundibugyo outbreak and how that work aligns with the 100 Days Mission.

CEPI’s Research Preparedness Programme is strengthening clinical trial infrastructure, systems and skills at frontline sites across West Africa.

CEPI has announced updates to its Scientific Advisory Committee (SAC), an external expert group providing independent scientific guidance across R&D programmes and outbreak preparedness activities.

CEPI convened the Global Vaccine Manufacturing Summit 2026 in London, UK, on 17th June. For the first time, financing institutions, vaccine developers, regulators, manufacturers, philanthropies and gl...

We're using knowledge built from the COVID-19 pandemic to strengthen the networks evaluating vaccine candidates that could fight the next big outbreak.

New funding will support the continued development of a pioneering vaccine platform.

CEPI funding will advance vaccine candidates towards clinical trials as quickly as possible.

A rapidly escalating epidemic of Bundibugyo ebolavirus in the Democratic Republic of the Congo and Uganda has triggered public health emergency declarations from both Africa CDC and WHO. This is now t...

A rapidly escalating epidemic of Bundibugyo ebolavirus in the Democratic Republic of the Congo and Uganda has triggered public health emergency declarations from both Africa CDC and WHO. This is now t...

A rapidly escalating epidemic of Bundibugyo ebolavirus in the Democratic Republic of the Congo and Uganda has triggered public health emergency declarations from both Africa CDC and WHO. This is now t...

CEPI funding will advance vaccine candidates towards clinical trials as quickly as possible.

Major new investments bolster global coalition's five-year plan to develop vaccines against the most dangerous pathogens and transform the world’s ability to tackle epidemic and pandemic threats.

The outbreak underscores why pandemic preparedness needs to start long before a public health emergency is declared.

From cutting edge preclinical models to ambitious next generation vaccines, researchers at VIDO are working with CEPI to help the world move faster - and smarter - when the next pandemic threat emerg...